American multinational pharma leader shaping GLP-1 therapies and global drug pricing debates
Eli Lilly has announced an all-cash deal to acquire AtaiBeckley for up to $2.8 billion upfront, with potential milestone payments. AtaiBeckley’s lead drug, a DMT-related nasal spray for treatment-resistant depression, is in Phase 3, with initial results expected in 2029. The deal signals growing pharma interest in psychedelic therapies amid regulatory momentum.
Novo Nordisk has filed a US lawsuit accusing Eli Lilly of false advertising over weight‑loss and diabetes drugs, arguing Lilly used outdated trial data to claim superiority. Lilly defends its campaigns, citing SURMOUNT‑5 results. The case centers on GLP-1 treatments and the race for market dominance, with potential damages and corrective advertising at stake.
The White House has proposed phased tariffs on imported generic medicines, arguing for a U.S.-based manufacturing boost. The plan starts with two years of zero tariffs, followed by 100% and then 200% levies, to spur domestic production. Industry groups warn the move could raise prices for patients while onshoring efforts face structural hurdles. Major manufacturers say margins are thin and shifting production could take years.
Regulators are reviewing a BMJ study linking GLP-1 receptor agonists to a higher risk of alopecia. The study compares hair-loss rates in GLP-1 users against SGLT-2 and DPP-4 inhibitors, with findings suggesting a 37% higher risk versus SGLT-2 and 68% higher versus DPP-4. Hair loss appears non-scarring and potentially reversible, often tied to weight loss and nutritional factors.
Barron’s reports Lilly’s plan to seek approval for its newest weight‑loss drug in 2027, signaling a potential pipeline expansion. The move follows a mixed earnings season for Danaher, with investors weighing the timing and impact on long‑term growth.
Foundayo, the oral GLP-1 weight-loss pill by Eli Lilly, has been authorised by the MHRA for weight management and type 2 diabetes. It will be available privately; NHS adoption depends on NICE evaluation. Several UK outlets report on uptake, pricing, side effects and competing pills, including Wegovy and Wegovy HD.
Lilly and Novo Nordisk have surpassed forecasts in Q2, widening the gap in the obesity-drug space. Lilly leads in the US with about 61% share; Novo raises full-year outlook but faces questions about Wegovy's growth and its pipeline. Investors are watching whether Novo can sustain momentum as competition intensifies.
CVS Health has raised its 2026 guidance, citing stronger profits from its insurance and retail pharmacy segments and a marked improvement in its Aetna unit. The company is expanding GLP-1 weight-loss access through MinuteClinic, while flagging higher medical costs and macro risks.
Eli Lilly has posted another quarter of strong results driven by Mounjaro and Zepbound, lifting full-year guidance. Novo Nordisk trails in growth momentum as it works to regain share and assure investors of a clear long-term path. Foundayo’s launch adds a new dimension to Lilly’s portfolio.
Lilly has filed six lawsuits targeting online sellers and clinics marketing retatrutide, a GLP-1 drug still in Phase 3 trials for obesity and diabetes, while US authorities report a surge in illicit shipments. The company says products sold online are unverified and unapproved, and warns of substantial health risks.
Norway’s sovereign wealth fund has posted a record first-half profit of about $185 billion as markets rally in tech names. It has disclosed a 0.05% stake in SpaceX, valuing the position at just over $1.2 billion, while its larger holdings include Nvidia, Apple and Microsoft. NBIM says the fund remains globally diversified and long-term oriented.
UK pharmacies are now able to offer orforglipron (Foundayo), the second GLP-1 pill for weight loss, following MHRA approval. The pill, manufactured by Eli Lilly, is available initially by private prescription while NICE assesses a potential NHS rollout in England. It targets BMI thresholds (30+, or 27-30 with weight-related conditions) and is taken daily with no food or water restrictions.
New observational data suggests Shingrix vaccination in older adults is associated with lower cardiovascular risk and reduced dementia incidence over multi-year follow-ups. Studies compare Shingrix to Zostavax and find reductions in heart disease, stroke, and dementia, with stronger signals in men for heart outcomes.
This week has seen several medical research and regulatory developments. Insilico Medicine has reported that its experimental drug rentosertib changed blood‑protein patterns that aging clocks read as three to four years younger in a small trial. Stanford teams have published studies showing they can grow hindbrain neurons separately and implant human cortical organoids into mice. The US health department has appointed permanent directors for three FDA centers.
Eli Lilly has agreed to acquire privately held Merida Biosciences for up to $2.88 billion in cash. Merida develops treatments targeting auto-antibodies for autoimmune diseases, with MER511 in early-stage trials for Graves’ disease and thyroid eye disease. The deal expands Lilly’s immunology pipeline amid strong demand for obesity drugs.
The White House has announced that most favored nation pricing will align U.S. drug prices with the lowest prices abroad, with several manufacturers set to participate. Officials say the move will lower costs for Americans and expand constraints on pricing practices.
Nvidia has reported stronger-than-expected results, guiding to 70% revenue growth for fiscal 2028 amid robust demand for AI chips. Amazon plans to buy 2 million Nvidia GPUs, underscoring sustained AI infrastructure buildout. The broader market questions whether hyperscaler demand will endure as memory-supply pressures persist.
A synthesis of recent sleep studies shows wearables may misjudge sleep quality, narcolepsy treatment advances gain regulatory traction, and weekend catch-up sleep ties to lower hypertension risk, prompting a nuanced view of how to monitor and improve sleep.
The Justice Department has reached a settlement with Abbott over the Sturgis, Michigan plant that produced a major share of U.S. infant formula. The settlement addresses unsanitary conditions and recalls tied to Cronobacter sakazakii, while Abbott maintains no admission of fault. Regulators say the plant’s issues contributed to a nationwide shortage.
Lilly has reported growth in the oral GLP-1 pill market and expansion plans, with one-third of new oral-GLP-1 patients on Foundayo. The company is also building a new manufacturing facility in Houston and reiterating its commitment to meeting rising demand as Medicare coverage broadens access to obesity drugs.
Novo has laid out a plan to diversify beyond Wegovy and Ozempic as it faces looming exclusivity losses. Capital Markets Day signals a push into cardiovascular, liver and blood disorders with a target to expand its pipeline, while investors question credibility and near-term milestones amid a evolving GLP-1 landscape dominated by Lilly.